Aquestive Therapeutics/$AQST
1D1W1MYTD1Y5YMAX
Capital at risk
About Aquestive Therapeutics
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
- Ticker
- $AQST
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 147
- Headquarters
- Warren, United States
- Website
- www.aquestive.com
AQST Metrics
BasicAdvanced
$612M
-
-$0.65
1.43
-
Price and volume
Market cap
$612M
Beta
1.43
52-week high
$7.55
52-week low
$2.93
Average daily volume
3.4M
Financial strength
Current ratio
7.191
Quick ratio
6.543
Long term debt to equity
-1.028
Total debt to equity
-1.043
Interest coverage (TTM)
-3.23%
Profitability
EBITDA (TTM)
-52.201
Gross margin (TTM)
67.04%
Net profit margin (TTM)
-144.63%
Operating margin (TTM)
-97.52%
Revenue per employee (TTM)
$370,000
Management effectiveness
Return on assets (TTM)
-29.20%
Return on equity (TTM)
121.12%
Valuation
Price to revenue (TTM)
10.838
Price to book
-10.82
Price to tangible book (TTM)
-10.82
Price to free cash flow (TTM)
-12.757
Free cash flow yield (TTM)
-7.84%
Free cash flow per share (TTM)
-0.383
Growth
Revenue change (TTM)
22.56%
Earnings per share change (TTM)
-5.58%
3-year revenue growth (CAGR)
5.15%
3-year earnings per share growth (CAGR)
16.66%
What the Analysts think about AQST
Analyst ratings (Buy, Hold, Sell) for Aquestive Therapeutics stock.
Analyst projections of the future price of Aquestive Therapeutics stock.
Bulls say / Bears say
Aquestive completed the new human-factors and pharmacokinetic studies for Anaphylm, with materially better packaging results and no administration errors in the self-administration arm. The company remains on track to resubmit the NDA in the third quarter, while the earlier FDA rejection did not question manufacturing controls or clinical comparability with auto-injectors. (Aquestive Therapeutics, Last10K)
If approved, Anaphylm could be the first non-invasive, orally delivered epinephrine product, giving Aquestive a differentiated route into a sizeable rescue market. The company also expects up to $75 million from RTW and $20 million from Oaktree for the launch, subject to approval and other conditions. (BioSpace, StockAnalysis)
The existing business is improving while the pipeline is being prepared: second-quarter revenue rose 38% year on year to $13.8 million, and the six-month adjusted EBITDA loss narrowed sharply. Aquestive ended June with $98.5 million of cash and has refinanced its debt, extending financial flexibility towards a potential launch. (StockAnalysis, StockTitan)
Anaphylm remains a binary regulatory bet after the FDA issued a Complete Response Letter over pouch-opening and administration problems. A resubmission is only planned, and the company cannot guarantee the accelerated review it intends to request. (Last10K, MarketBeat)
The company is still loss-making and consuming cash: its second-quarter filing showed $24.2 million of operating cash use over six months and a $56.6 million stockholders’ deficit, while 2026 guidance still implies a $30 million to $35 million adjusted EBITDA loss. Much of the planned launch funding is conditional on Anaphylm approval, leaving delay or financing risk for shareholders. (StockTitan, StockAnalysis)
Near-term proprietary diversification is limited. Libervant is only tentatively approved for patients aged 12 and over and is not expected to become eligible for full approval until January 2027, while its younger-patient filing is still under review. (StockTitan, Last10K)
Data summarised monthly by Lightyear AI. Last updated on 15 Sept 2026.
AQST Financial Performance
Revenues and expenses
AQST Earnings Performance
Company profitability
Upcoming events
No upcoming events
AQST News
AllArticlesVideos
Funds containing AQST
AllUSDGBPEUR
Fund name | Fund size | $AQST weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.03% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.03% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.